Chronic Phase Marker Market

Markers are broadly categorized as biomarkers or molecular markers and biochemical markers. Biomarker, also known as biological marker is commonly used to carry out detection of living organism which acts as a causative agent for specific diseases. It usually refers to a measurable indicator for various biological states or disease conditions in the human body. Biomarker is any substance that can be utilized as an indicator of specific disease condition and is often evaluated to detect pathogenic processes, normal biological process, or pharmacologic response to medical treatment. The elevated levels or absence of these biological markers may indicate the onset or late stage of a chronic disease. However, chronic phase indicates early stages of chronic leukemia which is a type of cancer in white blood cells. It constitutes high amounts of abnormal white blood cells in bone marrow and blood. Chronic phase markers are the biomarkers that help in detection of a disease condition with the presence of their elevated levels in patient?s body.

Chronic Phase Marker Market contains market size and forecasts of Chronic Phase Marker in Global, including the following market information:

Global Chronic Phase Marker Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Chronic Phase Marker market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Tumor Markers Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Phase Marker include Nordic BioSite, DiaSorin, Roche, Bristol-Myers Squibb, Hologic, QIAGEN, Philips, Johnson & Johnson and Lifesign, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Chronic Phase Marker companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Phase Marker Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Chronic Phase Marker Market Segment Percentages, by Type, 2021 (%)

Tumor Markers

Cardiac Markers

Thyroid Markers

Others

Global Chronic Phase Marker Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Chronic Phase Marker Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Diagnostic Laboratories

Global Chronic Phase Marker Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Chronic Phase Marker Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Phase Marker revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Chronic Phase Marker revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Nordic BioSite

DiaSorin

Roche

Bristol-Myers Squibb

Hologic

QIAGEN

Philips

Johnson & Johnson

Lifesign

Natus

BrainScope